Home > Healthcare > Pharmaceuticals > Finished Drug Form > Schizophrenia Drugs Market

Schizophrenia Drugs Market Share

Report ID: GMI10166
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Schizophrenia Drugs Market Share

The schizophrenia drugs sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative apps leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding the global footprint.

Schizophrenia Drugs Market Companies

Some of the eminent market participants operating in the schizophrenia drugs industry include:

AbbVie Inc.
Alkermes Public Limited Company
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company
Intra-Cellular Therapies, Inc.
Johnson & Johnson
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Recordati Industria Chimica e Farmaceutica S.p.A
SUMITOMO PHARMA CO., LTD
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Schizophrenia drugs industry size was worth USD 4.8 billion in 2023 and is projected to expand at 7.1% CAGR from 2024 to 2032, due to the rising prevalence of schizophrenia worldwide.

The second generation antipsychotics therapeutic class segment in the schizophrenia drugs industry is projected to record USD 6.3 billion by 2032, as they are known for their effectiveness in managing schizophrenia symptoms with fewer side effects compared to first-generation antipsychotics.

The paranoid schizophrenia type segment in the schizophrenia drugs industry accounted for USD 2.1 billion in revenue in 2023as it is one of the most common subtypes characterized by delusions and auditory hallucinations.

U.S. schizophrenia drugs industry is projected to record USD 3.3 billion by 2032, as the region is the hub for pharmaceutical innovation and research, with substantial investments in developing new therapies for mental health disorders.